ArticleInternational journal of molecular sciences2013
Oximes: inhibitors of human recombinant acetylcholinesterase. A structure-activity relationship (SAR) study.
Article in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Structure-Reactivity Relationships inInternational journal of molecular sciences · 2026Article
- Carltonine-derived compounds for targeted butyrylcholinesterase inhibition.RSC medicinal chemistry · 2024Article
- In Vitro Evaluation of Oxidative Stress Induced by Oxime Reactivators of Acetylcholinesterase in HepG2 Cells.Chemical research in toxicology · 2023Article
- Inhibitory Activity of 4-Benzylidene Oxazolones Derivatives of Cinnamic Acid on Human Acetylcholinesterase and Cognitive Improvements in a Mouse Model.Molecules (Basel, Switzerland) · 2023Article
- Structure-Guided Design ofInternational journal of molecular sciences · 2023Article
- Rational design and synthesis of modified natural peptides from Boana pulchella (anura) as acetylcholinesterase inhibitors and antioxidants.Amino acids · 2022Article
- FDA-Approved Oximes and Their Significance in Medicinal Chemistry.Pharmaceuticals (Basel, Switzerland) · 2022Review
- The Influence of Seasonality on Secondary Metabolite Profiles and Neuroprotective Activities of MossPlants (Basel, Switzerland) · 2022Article
- Design and synthesis of novel tacrine-indole hybrids as potential multitarget-directed ligands for the treatment of Alzheimer's disease.Future medicinal chemistry · 2021Article
- Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors andBiomolecules · 2020Article
- Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors.Biomolecules · 2019Article
- Toxic Injury to Muscle Tissue of Rats Following Acute Oximes Exposure.Scientific reports · 2019Article
- Development of small bisquaternary cholinesterase inhibitors as drugs for pre-treatment of nerve agent poisonings.Drug design, development and therapy · 2018Article
- Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy.Molecules (Basel, Switzerland) · 2017Article
- Novel Organophosphate Ligand O-(2-Fluoroethyl)-O-(p-Nitrophenyl)Methylphosphonate: Synthesis, Hydrolytic Stability and Analysis of the Inhibition and Reactivation of Cholinesterases.Chemical research in toxicology · 2016Article
- Primary Investigation for the Mechanism of Biatractylolide from Atractylodis Macrocephalae Rhizoma as an Acetylcholinesterase Inhibitor.Evidence-based complementary and alternative medicine : eCAM · 2016Article
- Discovery of New Classes of Compounds that Reactivate Acetylcholinesterase Inhibited by Organophosphates.Chembiochem : a European journal of chemical biology · 2015Article
- Oximes: inhibitors of human recombinant acetylcholinesterase. A structure-activity relationship (SAR) study.International journal of molecular sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acetylcholinesterase (AChE) reactivators were developed for the treatment of organophosphate intoxication. Standard care involves the use of anticonvulsants (e.g., diazepam), parasympatolytics (e.g., atropine) and oximes that restore AChE activity. However, oximes also bind to the active site of AChE, simultaneously acting as reversible inhibitors. The goal of the present study is to determine how oxime structure influences the inhibition of human recombinant AChE (hrAChE). Therefore, 24 structurally different oximes were tested and the results compared to the previous eel AChE (EeAChE) experiments. Structural factors that were tested included the number of pyridinium rings, the length and structural features of the linker, and the number and position of the oxime group on the pyridinium ring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.